Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Acute lymphoblastic leukemia (ALL) predominantly affects children but has poorer outcomes in adults. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a key consolidation therapy for high-risk patients, but the more commonly employed total body irradiation (TBI) regimen may be inaccessible in resource-limited settings, requiring alternative regimens. This retrospective study evaluated outcomes of 829 adult ALL patients who underwent HLA-matched allo-HSCT with a myeloablative, TBI-free regimen over two decades. The study compared overall survival (OS), disease-free survival (DFS), relapse incidence (RI), and non-relapse mortality (NRM) between pre- and post-2010 periods. Post-2010, 5-year OS improved from 38.3% to 48.1% (p = 0.0037), DFS from 36.6% to 42.0% (p = 0.027), and RI decreased from 47.5% to 40.8% (p = 0.012), with more notable improvements in patients ≥25 years. NRM remained stable (28.5% vs. 24.9%, p = 0.599). These findings suggest that a Busulfan-based, TBI-free regimen is a viable alternative, but further efforts are needed to reduce NRM and improve survival.